1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.

NCT02000596 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped funding withdrawn by sponsor

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Trastuzumab plus Pertuzumab
DRUG: Hormonal Therapy with Anastrozole and Fulvestrant
DRUG: Chemotherapy with Eribulin

Sponsor

University of Maryland, Baltimore

Collaborators

[object Object]